Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aminoglycosides | 2 | 2026 | 46 | 1.180 |
Why?
|
| Klebsiella pneumoniae | 2 | 2026 | 86 | 1.110 |
Why?
|
| Urinalysis | 2 | 2024 | 74 | 1.010 |
Why?
|
| Boronic Acids | 1 | 2026 | 49 | 0.940 |
Why?
|
| Protein Multimerization | 1 | 2026 | 149 | 0.910 |
Why?
|
| Bacterial Infections | 2 | 2024 | 322 | 0.830 |
Why?
|
| Abdominal Injuries | 1 | 2024 | 119 | 0.770 |
Why?
|
| Sucralfate | 1 | 2021 | 5 | 0.690 |
Why?
|
| Oral Ulcer | 1 | 2021 | 5 | 0.690 |
Why?
|
| Dehydration | 1 | 2021 | 41 | 0.680 |
Why?
|
| Child Abuse | 1 | 2024 | 218 | 0.680 |
Why?
|
| Anti-Ulcer Agents | 1 | 2021 | 114 | 0.650 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 1206 | 0.650 |
Why?
|
| Anti-Bacterial Agents | 4 | 2026 | 2551 | 0.650 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 76 | 0.630 |
Why?
|
| Prostatic Neoplasms | 1 | 2026 | 1386 | 0.540 |
Why?
|
| beta-Lactamases | 2 | 2026 | 218 | 0.400 |
Why?
|
| Fever | 2 | 2024 | 307 | 0.350 |
Why?
|
| Drug Combinations | 3 | 2026 | 278 | 0.330 |
Why?
|
| Infant | 9 | 2025 | 13306 | 0.300 |
Why?
|
| Aztreonam | 2 | 2026 | 5 | 0.300 |
Why?
|
| Azabicyclo Compounds | 2 | 2026 | 26 | 0.290 |
Why?
|
| Hepatitis E | 1 | 2008 | 8 | 0.290 |
Why?
|
| Klebsiella Infections | 2 | 2026 | 61 | 0.290 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2026 | 843 | 0.280 |
Why?
|
| Ceftazidime | 2 | 2026 | 49 | 0.280 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 315 | 0.250 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2026 | 8 | 0.240 |
Why?
|
| Providencia | 1 | 2025 | 3 | 0.240 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2025 | 6 | 0.230 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2025 | 34 | 0.230 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2025 | 58 | 0.230 |
Why?
|
| Epinephrine | 1 | 2025 | 143 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2025 | 117 | 0.210 |
Why?
|
| Anaphylaxis | 1 | 2025 | 83 | 0.210 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2025 | 176 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2026 | 381 | 0.200 |
Why?
|
| Receptors, Androgen | 1 | 2026 | 414 | 0.190 |
Why?
|
| Hospitals | 1 | 2025 | 434 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 323 | 0.180 |
Why?
|
| Humans | 14 | 2026 | 130574 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 3816 | 0.170 |
Why?
|
| Encephalitis, Japanese | 1 | 2020 | 18 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 470 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2024 | 510 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17653 | 0.160 |
Why?
|
| Male | 9 | 2026 | 64557 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2021 | 698 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8553 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1165 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1625 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 812 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2025 | 14987 | 0.130 |
Why?
|
| Female | 9 | 2025 | 70509 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2026 | 4665 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1932 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 166 | 0.070 |
Why?
|
| India | 1 | 2008 | 244 | 0.070 |
Why?
|
| Child | 5 | 2025 | 26145 | 0.070 |
Why?
|
| Animals | 2 | 2026 | 33899 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 9991 | 0.060 |
Why?
|
| Adolescent | 4 | 2025 | 20774 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2008 | 504 | 0.060 |
Why?
|
| Colistin | 1 | 2025 | 30 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2026 | 237 | 0.060 |
Why?
|
| Time Factors | 2 | 2025 | 6223 | 0.060 |
Why?
|
| Carbapenems | 1 | 2025 | 45 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1457 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 326 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2025 | 153 | 0.050 |
Why?
|
| Coinfection | 1 | 2025 | 188 | 0.050 |
Why?
|
| Communication Barriers | 1 | 2024 | 40 | 0.050 |
Why?
|
| Aftercare | 1 | 2024 | 152 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2008 | 1165 | 0.050 |
Why?
|
| Language | 1 | 2024 | 216 | 0.040 |
Why?
|
| Climate | 1 | 2020 | 26 | 0.040 |
Why?
|
| Mosquito Vectors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 28448 | 0.040 |
Why?
|
| Adult | 3 | 2025 | 31202 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 334 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 271 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2024 | 783 | 0.030 |
Why?
|
| United States | 1 | 2025 | 11820 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10993 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 20925 | 0.010 |
Why?
|